within Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GX09_Olopatadine;

model Olopatadine
  extends Pharmacolibrary.Drugs.ATC.S.S01GX09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01GX09</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Olopatadine is a selective histamine H1-receptor antagonist (antihistamine) used primarily to treat allergic conjunctivitis and allergic rhinitis. It is approved for topical use in the eye (as eye drops) and is widely used today for relief of ocular itching associated with allergic conjunctivitis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following single topical ocular administration of olopatadine 0.1% ophthalmic solution.</p><h4>References</h4><ol><li><p>Iyer, GR, et al., &amp; Chastain, JE (2015). Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 31(4) 204–210. DOI:<a href=&quot;https://doi.org/10.1089/jop.2014.0140&quot;>10.1089/jop.2014.0140</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25775192/&quot;>https://pubmed.ncbi.nlm.nih.gov/25775192</a></p></li><li><p>Vogelson, CT, et al., &amp; Yanni, JM (2004). Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. <i>Allergy and asthma proceedings</i> 25(1) 69–75. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15055565/&quot;>https://pubmed.ncbi.nlm.nih.gov/15055565</a></p></li><li><p>Namdar, R, &amp; Valdez, C (2011). Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. <i>Drugs of today (Barcelona, Spain : 1998)</i> 47(12) 883–890. DOI:<a href=&quot;https://doi.org/10.1358/dot.2011.47.12.1709243&quot;>10.1358/dot.2011.47.12.1709243</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22348913/&quot;>https://pubmed.ncbi.nlm.nih.gov/22348913</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Olopatadine;
